1.49
전일 마감가:
$1.49
열려 있는:
$1.49
하루 거래량:
784.92K
Relative Volume:
0.40
시가총액:
$273.21M
수익:
$137.74M
순이익/손실:
$-27.97M
주가수익비율:
-9.3125
EPS:
-0.16
순현금흐름:
$-9.61M
1주 성능:
+7.19%
1개월 성능:
+7.97%
6개월 성능:
-26.24%
1년 성능:
-5.10%
Heron Therapeutics Inc Stock (HRTX) Company Profile
명칭
Heron Therapeutics Inc
전화
(858) 251-4400
주소
4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA
HRTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
HRTX
Heron Therapeutics Inc
|
1.49 | 273.21M | 137.74M | -27.97M | -9.61M | -0.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Heron Therapeutics Inc Stock (HRTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-09 | 개시 | H.C. Wainwright | Buy |
| 2024-06-13 | 개시 | Rodman & Renshaw | Buy |
| 2024-04-23 | 개시 | CapitalOne | Overweight |
| 2024-03-13 | 재확인 | Needham | Buy |
| 2020-05-27 | 개시 | Guggenheim | Buy |
| 2020-02-20 | 재확인 | Needham | Buy |
| 2019-01-16 | 재확인 | Needham | Buy |
| 2018-04-05 | 개시 | Evercore ISI | Outperform |
| 2018-03-19 | 재확인 | Mizuho | Buy |
| 2018-03-01 | 재확인 | Needham | Buy |
| 2018-01-03 | 개시 | Leerink Partners | Outperform |
| 2017-09-27 | 개시 | Northland Capital | Outperform |
| 2017-02-27 | 개시 | Needham | Buy |
| 2016-10-26 | 개시 | Aegis Capital | Buy |
| 2016-09-06 | 재개 | Lake Street | Buy |
| 2016-05-03 | 개시 | Cantor Fitzgerald | Buy |
| 2015-12-10 | 개시 | Lake Street | Buy |
| 2015-09-23 | 재확인 | Leerink Partners | Outperform |
| 2015-09-02 | 개시 | BofA/Merrill | Buy |
| 2015-08-03 | 재확인 | Brean Capital | Buy |
| 2015-06-30 | 재확인 | JMP Securities | Mkt Outperform |
| 2015-06-19 | 재확인 | Leerink Partners | Outperform |
| 2014-08-07 | 개시 | Noble Financial | Buy |
모두보기
Heron Therapeutics Inc 주식(HRTX)의 최신 뉴스
Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Quarterly Trades: Can Heron Therapeutics Inc expand into new marketsStock Surge & Verified Momentum Stock Ideas - baoquankhu1.vn
VIX Spike: Is Heron Therapeutics Inc affected by consumer sentimentEarnings Growth Report & Fast Entry Momentum Alerts - baoquankhu1.vn
Aug Drivers: Is Heron Therapeutics Inc stock vulnerable to regulatory risksEntry Point & Smart Money Movement Alerts - Bộ Nội Vụ
Heron rises as preliminary revenue figures exceed estimates - MSN
Returns Recap: Does Heron Therapeutics Inc stock trade at a discount to peers - Bộ Nội Vụ
Great week for Heron Therapeutics, Inc. (NASDAQ:HRTX) institutional investors after losing 10% over the previous year - simplywall.st
Heron Therapeutics’ Q4 Earnings Beat Forecasts, Boosted by Acute Care Success - timothysykes.com
HC Wainwright Reaffirms Buy Rating for Heron Therapeutics (NASDAQ:HRTX) - Defense World
Heron Therapeutics’ Revenue Soars Beyond Expectations in Q4 2025 - StocksToTrade
Heron Therapeutics Revenue Exceeds Estimates with Strong Acute Care Performance - StocksToTrade
Heron Therapeutics Surpasses Revenue Expectations with Significant Growth - timothysykes.com
Heron Therapeutics sees Q4 revenue $40.5M, consensus $39.83M - Yahoo Finance
How supply chain issues affect Heron Therapeutics Inc. stockMarket Sentiment Review & Real-Time Stock Movement Alerts - Улправда
How Heron Therapeutics Inc. stock reacts to global recession fears2025 Price Momentum & Daily Profit Focused Stock Screening - Улправда
Can Heron Therapeutics Inc. stock surprise with earnings upsideCEO Change & Real-Time Buy Signal Alerts - Улправда
Heron Therapeutics Expands Strategic Vision Amid Market Fluctuations - StocksToTrade
Heron Therapeutics Reports Strong Preliminary Q4 2025 Revenue - TipRanks
HRTX: HC Wainwright & Co. Reiterates Buy Rating with $6 Price Ta - GuruFocus
Heron Therapeutics' (HRTX) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Heron Therapeutics stock soars after strong Q4 revenue growth By Investing.com - Investing.com Canada
Heron Therapeutics announces preliminary, unaudited Q4 results - marketscreener.com
Heron Therapeutics Reports Preliminary Fourth Quarter and Full-Year 2025 Financial Results - Quiver Quantitative
Heron Therapeutics Announces Preliminary, Unaudited Q4 and - GlobeNewswire
Will Heron Therapeutics Inc. stock gain from strong economy2025 Key Lessons & Long-Term Growth Stock Strategies - Улправда
What technical signals suggest for Heron Therapeutics Inc. stock2025 Retail Activity & Daily Profit Maximizing Tips - Улправда
Does Heron Therapeutics Inc. stock trade at a discount to peers2025 Bull vs Bear & High Yield Stock Recommendations - Улправда
How analysts rate Heron Therapeutics Inc. stock todayWeekly Gains Summary & Verified Momentum Stock Alerts - Улправда
Will Heron Therapeutics Inc. stock maintain dividend yield2025 Volatility Report & Long Hold Capital Preservation Tips - Улправда
Can Heron Therapeutics Inc. stock sustain market leadershipIndustrial Stocks Review & High Profit Growth Stocks - ulpravda.ru
Will Heron Therapeutics Inc. stock outperform tech sector in 20252026 world cup usa national team group stage star players high defensive line tactical prediction insights - Улправда
Is Heron Therapeutics Inc AXD2 a good long term investmentConsumer Goods Stocks & Small Capital Gains - earlytimes.in
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Exit Recap: Does Heron Therapeutics Inc stock trade at a discount to peers2025 Market WrapUp & Verified Momentum Watchlists - Bộ Nội Vụ
What analysts say about Heron Therapeutics Inc AXD2 stockContrarian Investment Ideas & High Return Investment Growth - earlytimes.in
Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Investor Mood: Will Heron Therapeutics Inc stock outperform tech sector in 2025Bear Alert & Long Hold Capital Preservation Tips - moha.gov.vn
Is Heron Therapeutics Inc. stock attractive for income investorsJuly 2025 Highlights & Capital Protection Trading Alerts - Улправда
Is Heron Therapeutics Inc. stock cheap at current valuationJuly 2025 Drop Watch & Safe Investment Capital Preservation Plans - DonanımHaber
Can Heron Therapeutics Inc. stock sustain revenue growthJuly 2025 Review & Growth Focused Stock Reports - Улправда
Is Heron Therapeutics Inc. stock gaining market shareInflation Watch & Community Consensus Trade Alerts - Улправда
Heron Therapeutics Earnings Notes - Trefis
Is Heron Therapeutics Stock Built to Withstand More Downside? - Trefis
Congress Park Capital LLC Acquires 621,908 Shares of Heron Therapeutics, Inc. $HRTX - Defense World
Heron Therapeutics, Inc. (NASDAQ:HRTX) Stock Catapults 27% Though Its Price And Business Still Lag The Industry - simplywall.st
Heron Therapeutics, Inc. (NASDAQ:HRTX) is favoured by institutional owners who hold 57% of the company - Yahoo Finance
Heron Therapeutics Appoints Thomas Cusack to Board - MSN
Heron Therapeutics Reports Strong Q3 2025 Revenue Growth - MSN
Heron Therapeutics Inc (HRTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Heron Therapeutics Inc 주식 (HRTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Morgan Adam | Director |
Aug 08 '25 |
Buy |
1.50 |
1,766,546 |
2,649,819 |
8,753,290 |
자본화:
|
볼륨(24시간):